我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
0
0 进行中
药物批准
10
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
FDA
Food and Drug Administration
• Alzinova has successfully raised capital to advance preparations for Phase II clinical trials of its Alzheimer's disease therapeutic candidate, following promising early-stage results. • The company is now fully focused on Phase II trial preparations, as highlighted in Carnegie's commissioned research reports and confirmed in Alzinova's Q1 review. • This development represents a significant milestone in Alzinova's clinical pipeline, potentially offering a new approach to addressing the unmet needs in Alzheimer's disease treatment.
